

**DETERMINATION OF TERPENOID PROFILE IN DRY CANNABIS FLOWERS AND
EXTRACTS OBTAINED FROM DIFFERENT CANNABIS VARIETES**

ABSTRACT

Aim: The aim of this study was to determine terpenoid profile in dry cannabis flowers obtained from different varieties of cannabis plant and to investigate what happens to terpenes after the extraction purification process. For that purpose, a verification of GC/MS method for determination of terpenes in cannabis flowers and extracts was done to demonstrate that the analytical method is suitable for intended analysis.

Methods: The concentration of terpenes was determined in the starting material (dry flowers) before extraction and after extraction in obtained decarboxylated and distilled cannabis extracts using the same GC/MS analytical method. The extraction was performed using 96% ethanol as a solvent.

Results: The results obtained indicate that dry flowers derived from different cannabis varieties can be distinguished only by a terpenoid profile which is at the same time a fingerprint or a specificity that is characteristic of each variety and conformation for expected pharmacological effect. Standardization of the cannabis-based extracts can be confirmed as well by determination of terpenoid profile before to be incorporate in the final pharmaceutical dosage forms.

Conclusion: The main carriers of pharmacological effects in cannabis flowers or extracts are cannabinoids. Terpenes act synergistically with cannabinoids. Since there is no monograph in the European Pharmacopeia for quality testing of cannabis extracts, currently a revised monograph for cannabis extracts, published in the German Pharmacopoeia, has instructed the obligatory procedure for quality testing of cannabis extracts in the European Union. Following this monograph, the purification process is necessary to achieve a final concentration of cannabinoids (Tetrahydrocannabinol) of more than 95% in the final active pharmaceutical ingredient. The purification process removes terpenes that have proven synergistically pharmacological effects with cannabinoids.

Keywords: Terpenes; terpenoid profile; cannabis extracts; GC/MS determination; fingerprint

1. INTRODUCTION

Cannabis sativa L. (Cannabaceae) is the most frequently used plant, yet notorious and controversial, but considered to have therapeutic potential [1]. Several cannabis-based medicines are now available for the treatment of various pathological conditions such as treatment of pain in cancer patients, treatment of nausea and vomiting induced by chemotherapy, loss of appetite and treatment of cachexia in patients with cancer and acquired immunodeficiency syndrome (AIDS), treatment of neuropathic and chronic pain and spasticity in multiple sclerosis [2-6].

Cannabis is a plant that contains more than 1,000 different chemical ingredients, which vary depends on the chemotype (chemical phenotype) of the strain. Chemotypes denote plants of the same genus that are practically identical in appearance but produce essential oil containing different major ingredients that vary within one botanical strain [7].

1.1 Importance of terpenes / terpenoids

An essential oil (extract) derived from cannabis plants primarily contains cannabinoids which are the main carriers of pharmacological effects and terpenes / terpenoids, that act synergistically with cannabinoids in exhibiting a pharmacological effect. Terpenes / terpenoids are also largely responsible for the characteristic aroma of cannabis extracts.

Terpenes / terpenoids itself have a wide range of pharmacological actions, such as antifungal, antiviral, anticancer, anti-inflammatory, antihyperglycemic, antiparasitic, antioxidant and antimicrobial. For example, monoterpene myrcene which is the smallest terpene, has antipsychotic, antioxidant, analgesic, anti-inflammatory, sedative, muscle relaxant and anticancer effects [8–10]. Caryophyllene has gastroprotective, analgesic, anticancer, antifungal, antibacterial, antidepressant, anti-inflammatory, antiproliferative, antioxidant, and neuroprotective effects [11]. α -pinene has antibacterial, anti-inflammatory, broncho dilatory, antiseptic and gastroprotective pharmacological effects, while β -pinene has only an antiseptic effect [12]. Linalool is a terpene that acts as a sedative, antipsychotic, anticonvulsant, anxiolytic, anesthetic, antidepressant, analgesic, antiepileptic and antineoplastic. Terpineol has an antioxidant, antimicrobial, and relaxing effect, while caryophyllene has analgesic, anticancer and antifungal effects [13]. Other terpenes like phellandrene and ocimene, has only an antifungal effect and they are used to treat different digestive disorders [14-15]. Camphene helps in treatment of cardiovascular diseases, while guaiaol has an antitumor effect [16]. α -humulene has antibacterial, anti-inflammatory, and antitumor effects [17], nerolidol antiparasitic [18, 19], and citral has an antifungal, antimicrobial, antiproliferative, cytotoxic, anticancer, and antitumor effect [20–25].

Due to their synergistic effect, several therapeutic approaches based on the combined use of cannabinoids and terpenes have recently been developed [26-29]. Considering that different terpenes have different pharmacological effects, standardization of these products, which can be very heterogeneous [30] depending on the variety of plants from which they are obtained, is an important prerequisite for confirming the quality and expected pharmacological effect [31]. This is especially important if we consider that the terpenoid profile is a fingerprint or a specificity that is characteristic of each variety.

Therefore, our goal was to develop or verify the GC / MS method for determination of 35 terpenes and to monitor their content in a cannabis dry flower from different varieties as well as in cannabis extracts obtained from different varieties of dried cannabis flowers.

2. MATERIAL AND METHODS

2.1 Chemicals and reagents

Standards for cannabis terpenes as a Reference material were supplied by Restek and Sigma Aldrich (Table 1). Helium gas was supplied by Messer.

Table 1. Standards for cannabis terpenes used as a Reference material

Substance name	Lot No:	Manufacturer	Expiration date
Cannabis terpenes standard #1	A0155278	Restek	11.2021
Cannabis Terpene Mix A	LRAC3834	Sigma Aldrich	09.2022
Cannabis Terpene Mix B	LRAC7120	Sigma Aldrich	09.2023

2.2 Apparatus

Terpene analysis were performed on a GCMS-QP2010SE single quadrupole mass spectrometer with static headspace (HS-20) with loop and autosampler for sample introduction.

2.3 Instrument operating conditions and method parameters

Instrument operating conditions and method parameters [32] are shown in Table 2. Verification of the method was fully implemented.

2.4 Standard solutions and calibration curves

Three sets of standards were used to obtain a more complete terpene profile. Standard one, purchased from Restek in a 2500 µg/mL stock solution, and Standard two and three, purchased from Sigma Aldrich (SPEX mix A and SPEX mix B) in a 100 µg/mL stock solution, which included 35 different terpenes in total.

Full evaporation headspace technique (FET) was used for quantitation. A five-point calibration curves were created from the Restek terpene standard with concentration ranging from 78-2500 $\mu\text{g/mL}$ and Sigma Aldrich terpene standards (mix A and mix B) with concentrations ranging from 12.5-100 $\mu\text{g/mL}$. An aliquot of 10 μL of the standard was placed in a 10mL headspace vial and capped. All points on the calibration curve were run in replicates of six.

Table 2. Instrument operating conditions and method parameters

Head Space	HS-20 Loop Model
Operation Mode	Static headspace with loop
Sample	10 μl sample volume 10 ml headspace vial
Equilibration	30 minutes at 150°C
Sample Loop	1 ml loop Vial pressurization 1.00 min, equilibration 0.20 min Loop load time 1.00 min, equilibration 0.20 min Injection time 1.0 min
Sample Pathway Temperature	150°C
Transfer Line Temperature	150°C
Gas Chromatogram	GC-2010 Plus
Injection	Split injection from HS-20, with 50:1 split ration
Column	Rxi-624 Sil MS 30.0 m x 0.25 mm x 1.40 μm Helium carrier gas Constant linear velocity, 47.2 cm/sec Column Flow 1.64 ml/min Purge Flow 3.0 m/min
Oven program	80°C, hold 1.0 min 12°C/min to 150°C, hold 1.0 min 9°C/min to 250°C, hold 1 min Total GC run time 19.94 min Total cycle time 24 min
Detector	GCMS-QP2010 SE
Operating mode	Selected Ion Monitoring (SIM) and SCAN
Ion Source	200°C, EI mode, 70eV
Solvent Cut Time	2 min
MS Interface	300°C

2.5 Verification of the method

The proposed method was verified according to the guidelines set by the International Conference of Harmonization for validation of analytical procedures [33, 34]. The precision and reproducibility of the proposed method were evaluated by performing six replicate analyses of the standard solutions for five different concentrations. Relative standard deviations were calculated to obtain the precision of the method. The full mass scan was done for all standard mix solutions to conform the specificity / selectivity of the method. To confirm the linearity of the method standard solutions in at least five different concentrations was prepared for

all analytes. The limit of detection and limit of quantification for each analyte were calculated from standard error, slope, and analyte response.

2.6 Sample preparation (dry flower of cannabis extract)

FET was used for quantitation. 30mg of the dry cannabis flower or cannabis extract (decarboxylated or distilled oil) were weighed into a headspace vial and capped. Calculations of the quantity of different terpenes was done using calibration curves for each terpene. Analyze was done on nine different strains of cannabis plant and two decarboxylated and two distilled cannabis extracts obtained from two different strains of cannabis plant. The extraction was performed using 96% ethanol as a solvent.

3. RESULTS AND DISCUSSION


3.1. Verification of the method

The precision and reproducibility of the proposed method were evaluated by performing six replicate analyses of the standard solutions for five different concentrations used for creation of calibration curves. Relative standard deviations (RSD) were calculated for each terpene. RSD for each terpene in each concentration after 6 replicate determinations was lower than 7% [35].

The typical chromatograms and calibration curves of the standard solutions of each terpene are shown in Figure 1-1, Figure 1-2 and Figure 1-3. Coefficient of correlation was greater than 0.99.

The full mass scan was done for all standard mix solutions to conform the specificity / selectivity of the method. At least 2 qualifier ions were used for identification and one quantifier ion for quantification. The results are shown in Table 3.

Limit of detection / Limit of quantification were calculated from standard error, slope, and analyte response. The results calculated as numerical (absolute) value from the calibration curve are shown in Table 4.







Figure 1-1. Typical chromatograms and calibration curves of the standard solutions for terpene testing







Figure 1-2. Typical chromatograms and calibration curves of the standard solutions for terpene testing






Figure 1-3. Typical chromatograms and calibration curves of the standard solutions for terpene testing

Table 3. Retention time and analyte transition for different terpenes

Terpene	Retention time	Precursor Ion	Product Ion (Quantifier)	Product Ion (Qualifier)
alpha-Pinene	5.93	93	92	91
Camphene	6.24	93	121	79
beta-Myrcene	6.61	93	41	69
beta-Pinene	6.65	93	69	41
3-Carene	7.015	93	91	79
Alpha terpinene	7.16	121	93	136
trans-beta-Ocimene	7.245	93	92	91
Limonene	7.325	68	93	67
Cymene	7.38	119	134	91
beta-Ocimene	7.485	93	91	80
gamma-Terpinene	7.76	93	91	80
Terpinolene	8.275	93	121	136
Linalol	8.88	71	93	55
L-Fenchone	9.055	81	69	41
Fenchol, exo-	9.59	81	80	43
Isopulegol	9.97	67	81	69
Camphor	10.265	95	81	108
Isoborneol	10.4	95	110	93
Menthol	10.47	81	71	95
Borneol	10.59	95	110	41
alpha-Terpineol	10.76	59	93	121
Citronellol	11.165	96	41	55
Geraniol	11.6	69	41	68
Pulegone	11.685	81	152	67
Geranyl acetate	13.31	69	41	43
Alpha-Cedrene	14.145	119	93	105
beta-Caryophyllene	14.255	93	133	69

alpha-Humulene	14.805	93	80	121
cis-Nerolidol	15.79	69	93	41
trans-Nerolidol	16.22	69	93	41
Guaiol	17.09	161	59	105
Cedrol	17.505	95	150	151
alpha-Bisabolol	18.075	109	119	69
beta-Eudesmol	18.095	59	149	108
Phytol	19.325	95	68	82

Table 4. Limit of detection / Limit of quantification of different terpenes, calculated as numerical (absolute) value from the calibration curve

Terpene	Limit of Detection	Limit of Quantification
alpha-Pinene	0.544	1.649
Camphene	0.445	1.349
beta-Myrcene	0.547	1.658
beta-Pinene	0.508	1.539
3-Carene	0.478	1.449
Alpha terpinene	0.387	1.174
trans-beta-Ocimene	0.573	1.738
Limonene	0.483	1.464
Cymene	0.327	0.993
beta-Ocimene	0.521	1.580
gamma-Terpinene	0.454	1.376
Terpinolene	0.446	1.35
Linalol	0.661	2.003
L-Fenchone	0.031	0.094
Fenchol, exo-	0.019	0.060
Isopulegol	0.691	2.095
Camphor	0.038	0.117
Isoborneol	0.026	0.079
Menthol	0.030	0.091
Borneol	0.028	0.086
alpha-Terpineol	0.032	0.097
Citronellol	0.060	0.182
Geraniol	1.140	3.456
Pulegone	0.024	0.074
Geranyl acetate	0.019	0.058
Alpha-Cedrene	0.027	0.081
beta-Caryophyllene	0.584	1.770
alpha-Humulene	0.929	2.816

beta-Caryophyllene	ND	ND	ND	4.542	18.268	23.480	33.033	25.800	19.883
alpha-Humulene	7.759	7.260	3.141	2.932	4.962	5.844	7.798	6.783	5.440
cis-Nerolidol	ND	ND	ND	ND	ND	ND	ND	ND	ND
trans-Nerolidol	ND	ND	ND	0.169	1.114	1.181	2.272	1.322	1.120
Guaiol	ND	ND	ND	1.154	1.303	ND	ND	ND	0.181
Cedrol	ND	ND	ND	ND	ND	ND	ND	ND	ND
alpha-Bisabolol	ND	ND	ND	0.571	1.019	0.183	0.243	0.604	0.680
beta-Eudesmol	ND	ND	ND	1.371	1.620	0.099	0.105	0.146	0.315
Phytol	ND	ND	ND	0.014	ND	ND	ND	ND	ND

*BB (Big Bud), AK (AK-47), WW (White Widow), HE (Herijuana), SG (Strawberry Glue), LS (La S.A.G.E), GE (Gelato), FC (French Cookies), AFG (Afghan Berry)

ND – Not Detected

Table 6. Determination of major terpenoids in cannabis extracts obtained from different varieties of cannabis flower

Cannabis strain	WW*		
Terpene	Terpenes (%) in dry cannabis flowers	Terpenes (%) in Decarboxylated oil	Terpenes (%) in Distillated oil
alpha-Pinene	15.287	4.089	0.69
beta-Myrcene	68.887	15.225	1.90
beta-Pinene	6.438	2.860	0.11
Cannabis strain	BB*		
Terpene	Terpenes (%) in dry cannabis flowers	Terpenes (%) in Decarboxylated oil	Terpenes (%) in Distillated oil
alpha-Pinene	10.997	1.27	0.73
beta-Myrcene	62.998	42.91	3.76
Limonene	4.804	3.70	1.07

*Decarboxylated and Distillated oil obtained from cannabis strain WW (White Widow) and BB (Big Bud)

Typical chromatogram for chromatographic separation of all terpenes in standard solution is shown in Figure 2.




Figure 2. Typical chromatogram for chromatographic separation of terpenes

4. DISSCUSION

Terpenes, which are the basic ingredients of essential oils in many plants have been used for thousands of years for different therapeutic purposes. Studies in animal models and humans have identified analgesics, antimicrobials, anti-inflammatory and similar therapeutic properties. The main focus of researchers for the therapeutic purposes of cannabis-based medicines have been cannabinoids primarily Δ^9 -tetrahydrocannabinol (THC), while terpenes and potential interactions between terpenes and cannabinoids has barely been studied at all when the cannabis-based medicines are consumed for medical purposes [36].

The hypothesized synergistic interactions between different cannabinoids and terpenes to obtain unique pharmacological effects have been investigated in several preclinical and some clinical studies. There is skepticism in the literature and remains unclear with insufficient evidence from preclinical studies whether terpenes can act synergistic with cannabinoids [37-39]. If terpenes can be shown to modulate cannabinoid activity, it could provide a powerful tool to improve cannabinoid therapy.

Recently studies have been conducted to evaluate the functional and modulatory actions of various terpenes in vivo and in vitro, both alone and in combination with an established cannabinoid agonist. The results of this studies establish direct interaction between cannabinoids and terpenes demonstrating that terpenes can selectively modulate pharmacological agonist activity of cannabinoids. This study is the first that shows that terpenes and cannabinoids can produce an additive effect when combined [36]. The mechanisms of synergistic action between terpenes and cannabinoids at the molecular level is still unknown. Two alternatives are (1) direct modulation of membrane shifting CB1 receptors activation and (2) terpene modulation of endocannabinoid synthesis or degradation, which results in CB1 receptors activation. But the notable aspect of this study was the generally high concentrations of terpenes needed to see activation [36].

In our case, we conducted tests for determination of terpenes in cannabis dry flowers and extracts. Since there is no monograph in the European Pharmacopeia (Ph.Eur.) for quality testing of cannabis flower and extracts, currently a revised monograph for cannabis flower (cannabis floss) and cannabis extracts, published in the German Pharmacopoeia in 2018 (3) and 2020, by the Federal Institute for Drugs and Medical Devices (BfArM) has instructed the obligatory procedure for quality testing of cannabis flowers in the European Union [40]. Following these monographs, the purification process of the cannabis crude extract is necessary to achieve a final

concentration of THC of more than 95% in the final active pharmaceutical ingredient (API) as it is noted in the monograph. With the analysis performed we have shown that the purification process removes terpenes from the final extracts.

The percentage of major terpene beta-Myrcene which is the smallest terpene with proved antipsychotic, antioxidant, analgesic, anti-inflammatory, sedative, muscle relaxant and anticancer effects in the starting material decreased from 68 to 15% in decarboxylated and, 1.9% in distilled cannabis oil after purification.

The percentage of second major terpene alpha-Pinene which has proven antibacterial, anti-inflammatory, broncho dilatory, antiseptic and gastroprotective pharmacological effects in the starting material decreased from 15 to 5% in decarboxylated and, 0.7% in distilled cannabis oil after purification.

Considering that generally high concentrations of terpenes are needed to see cannabinoid CB1 receptors activation the question that arises is whether the process of purification to obtain an API with a higher concentration of cannabinoids is justified.

5. CONCLUSION

Cannabis is a plant that contains more than a thousand different chemical ingredients, which vary depends on the chemotype of the strain. The main carriers of pharmacological effects in cannabis flowers or extracts are cannabinoids. Terpenes itself have a wide range of pharmacological actions, such as antifungal, antiviral, anticancer, anti-inflammatory, antimicrobial, and act synergistically with cannabinoids in exhibiting a pharmacological effect. At the same time terpenes are fingerprint or a specificity that is characteristic of each variety, which is very important for standardization of the cannabis-based extracts. Since there is no monograph in the European Pharmacopeia for quality testing of cannabis extracts, revised monograph for cannabis extracts, published in the German Pharmacopoeia, is obligatory procedure for quality testing of cannabis extracts in the European Union. Following this monograph, the purification process is necessary to achieve a final concentration of tetrahydrocannabinol of more than 95% in the final active pharmaceutical ingredient. With the analysis performed we have shown that the purification process removes terpenes from the final extracts. The question that arises is connected to the pharmacological effect on cannabis-based medicines obtained from cannabis active pharmaceutical ingredients in which terpenes have been removed.

COMPETING INTERESTS DISCLAIMER:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly use products in our area of research and country. There is absolutely no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any

litigation but for the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by personal efforts of the authors.

REFERENCES

1. Whiting PF, Wolff RF, Deshpande S, Di Nisio M, Duffy S, Hernandez AV, Keurentjes JC, Lang S, Misso K, Ryder S. Cannabinoids for medical use: a systematic review and meta-analysis. *JAMA*. 2015; 313:2456–2473
2. Tijana Serafimovska, Jasmina Tonic Ribarska, Dejan Trajkov, Marija Darkovska Serafimovska, Gjoshe Stefkov. Approved indications for cannabis-based preparations. *IOSR Journal of Pharmacy*; 2021; 11(9):36-40
3. Tijana Serafimovska, Marija Darkovska-Serafimovska, Gjoshe Stefkov, Zorica Arsova-Sarafinovska, Trajan Balkanov. Pharmacotherapeutic Considerations for Use of Cannabinoids to Relieve Symptoms of Nausea and Vomiting Induced by Chemotherapy. *Folia Medica* 2020; 62(4):668-78
4. Amato L, Minozzi S, Mitrova Z, Parmelli E, Saulle R, Cruciani F, Vecchi S, Davoli M. Systematic review of safeness and therapeutic efficacy of cannabis in patients with multiple sclerosis, neuropathic pain, and in oncological patients treated with chemotherapy. *Epidemiol Prev*. 2017; 41:279–293
5. Rudroff T, Honce JM. Cannabis and multiple sclerosis – The way forward. *Front Neurol*. 2017; 8:299
6. Lee G, Grovey B, Furnish T, Wallace M. Medical cannabis for neuropathic pain. *Curr Pain Headache Rep*. 2018; 22:8
7. Lumír Ondřej, Hanuš Yotam Hod. Terpenes/Terpenoids in Cannabis: Are They Important? *Med Cannabis Cannabinoids*. 2020; 3:25–60
8. Zaklin R. Terpene therapy. Abstracts of Papers, 256th ACS National Meeting & Exposition, Boston, MA, 2018; August 19–23, CHAS-50
9. Gulluni N, Re T, Loiacono I, Lanzo G, Gori L, Macchi C, et al. Cannabis essential oil: a preliminary study for the evaluation of the brain effects. *Evid Based Complement Alternat. Med*. 2018; 1709182
10. Jansen C, Shimoda LMN, Kawakami JK, Ang L, Bacani AJ, Baker JD, et al. Myrcene and terpene regulation of TRPV1. *Channels*. 2019; 13(1): 344–66
11. Francomano F, Caruso A, Barbarossa A, Fazio A, La Torre C, Ceramella J, et al. β -Caryophyllene: a sesquiterpene with countless biological properties. *Appl Sci*. 2019; 9(24): 5420.
12. Salehi B, Upadhyay S, Orhan IE, Jugran AK, Jayaweera SLD, Dias DA, et al. Therapeutic potential of α - and β -pinene: a miracle gift of nature. *Biomolecules*. 2019; 9: 738.
13. Khaleel C, Tabanca N, Buchbauer G. α -Terpineol, a natural monoterpene: a review of its biological properties. *Open Chem*. 2018; 16(1): 349–61.
14. Zhang JH, Sun HL, Chen SY, Zeng L, Wang TT. Anti-fungal activity, mechanism studies on α -

- phellandrene and nonanal against *Penicillium cyclopium*. *Bot Stud.* 2017; 58(1): 13.
15. Thakre AD, Mulange SV, Kodgire SS, Zore GB, Karuppaiyl SM. Effects of cinnamaldehyde, ocimene, camphene, curcumin and farnesene on *Candida albicans*. *AiM.* 2016; 6(9): 627–43.
 16. Yang X, Zhu J, Wu J, Huang N, Cui Z, Luo Y, et al. (–)-Guaiol regulates autophagic cell death depending on mTOR signaling in NSCLC. *Cancer Biol Ther.* 2018; 19(8): 706–14.
 17. Jang H-I, Ki-Jong R, Eom Y-B. Antibacterial and antibiofilm effects of α -humulene against *Bacteroides fragilis*. *Can J Microbiol.* 2020; 66:389–399.
 18. Silva MP, de Oliveira RN, Mengarda AC, Roquini DB, Allegretti SM, Salvadori MC, et al. Antiparasitic activity of nerolidol in a mouse model of schistosomiasis. *Int J Antimicrob Agents.* 2017; 50(3): 467–72
 19. Alonso L, Fernandes KS, Mendanha SA, Goncalves PJ, Gomes RS, Dorta ML, et al. In vitro antileishmanial and cytotoxic activities of nerolidol are associated with changes in plasma membrane dynamics. *Biochim Biophys Acta Biomembr.* 2019; 1861(6): 1049–56
 20. Thomas ML, de Antueno R, Coyle KM, Sultan M, Cruickshank BM, Giacomantonio MA, et al. Citral reduces breast tumor growth by inhibiting the cancer stem cell marker ALDH1A3. *Mol Oncol.* 2016; 10(9): 1485–96
 21. Sheikh BY, Sarker MMR, Kamarudin MNA, Mohan G. Antiproliferative and apoptosis inducing effects of citral via p53 and ROS-induced mitochondrial-mediated apoptosis in human colorectal HCT116 and HT29 cell lines. *Biomed Pharmacother.* 2017; 96: 834–46
 22. Sanches LJ, Marinello PC, Panis C, Fagundes TR, Morgado-Diaz JA, de-Freitas-Junior JC, et al. Cytotoxicity of citral against melanoma cells: the involvement of oxidative stress generation and cell growth protein reduction. *Tumour Biol.* 2017; 39(3): 1010428317695914
 23. Zielińska A, Martins-Gomes C, Ferreira NR, Silva AM, Nowak I, Souto EB. Anti-inflammatory and anti-cancer activity of citral: optimization of citral-loaded solid lipid nanoparticles (SLN) using experimental factorial design and LUMiSizerR. *Int J Pharm.* 2018; 553(1–2): 428–40
 24. Kremer JL, Melo GP, Marinello PC, Bordini HP, Rossaneis AC, Sabio LR, et al. Citral prevents UVB-induced skin carcinogenesis in hairless mice. *J Photochem Photobiol B Biol.* 2019; 198: 111565
 25. Nigjeh SE, Yeap SK, Nordin N, Rahman H, Rosli R. In vivo anti-tumor effects of citral on 4T1 breast cancer cells via induction of apoptosis and downregulation of aldehyde dehydrogenase activity. *Molecules.* 2019; 24(18):3241
 26. Tarmo Nuutinen. Medicinal properties of terpenes found in *Cannabis sativa* and *Humulus lupulus*. *European Journal of Medicinal Chemistry.* 2018; 157:198-228
 27. Marco Ternelli, Virginia Brighenti, Lisa Anceschi, Massimiliano Poto, Davide Bertelli, Manuela Licata, Federica Pellati. Innovative methods for the preparation of medical Cannabis oils with a high content of both cannabinoids and terpenes. *Journal of Pharmaceutical and Biomedical Analysis.* 2020; 186:113296
 28. Tomko AM, Whynot EG, Ellis LD, Dupré DJ. Anti-Cancer Potential of Cannabinoids, Terpenes, and Flavonoids Present in Cannabis. *Cancers.* 2020; 12(7):1985.
 29. Eric J. Downer Anti-inflammatory Potential of Terpenes Present in *Cannabis sativa* L. *Neurosci.* 2020; 11(5):659–662
 30. Potter DJ, Hammond K, Tuffnell S, Walker C, Di Forti M. Potency of Δ^9 -tetrahydrocannabinol and

- other cannabinoids in cannabis in England in 2016: Implications for public health and pharmacology. *Drug Test Anal.*; 2018; 10(4):628–35.
31. Vujanovic, V.; Korber, D.R.; Vujanovic, S.; Vujanovic, J.; Jabaji, S. Scientific Prospects for Cannabis-Microbiome Research to Ensure Quality and Safety of Products. *Microorganisms* 2020; 8:290
 32. Shimadzu. Simplified Cannabis Terpene Profiling by GCMS. Application news No. SSI-GCMS-1604
 33. ICH Q2R1: Validation of Analytical Procedures: Text and Methodology. Proceeding of the International Conference on Harmonization of Technical Requirements for the Registration of Drugs for Human Use, Geneva, Switzerland, 1996.
 34. ICH, Guideline on Analytical Method Validation, Proceeding of International Convention on Quality for the Pharmaceutical Industry, Toronto, Canada, 2002.
 35. EU, Council Directive 96/23/EC concerning the performance of analytical methods and the interpretation of results (12 August 2002), notified under document number C. 2002; 3044 (2002/657/EC)
 36. Justin E. LaVigne, Ryan Hecksel , Attila Keresztes & John M. Streicher. Cannabis sativa terpenes are cannabimimetic and selectively enhance cannabinoid activity. *Scientific Reports*. 2021; 11:8232 <https://doi.org/10.1038/s41598-021-87740-8>
 37. Harris, H. M. et al. Role of cannabinoids and terpenes in cannabis-mediated analgesia in rats. *Cannabis Cannabinoid Res.*2019; 4(3):177–182
 38. Cogan, P.S. The 'entourage effect' or 'hodge-podge hashish': The questionable rebranding, marketing, and expectations of cannabis polypharmacy. *Expert Rev. Clin. Pharmacol.* 2020; 1–11
 39. Santiago, M., Sachdev, S., Arnold, J. C., McGregor, I. S. & Connor, M. Absence of entourage: Terpenoids commonly found in cannabis sativa do not modulate the functional activity of $\Delta(9)$ -THC at human CB(1) and CB(2) receptors. *Cannabis Cannabinoid Res.*2019; 4(3):165–176
 40. German Pharmacopoeia 2020 (DAB 2020), Monograph Cannabisblüten and Monograph Eingestellter Cannabisextrakt.